Neurocrine Biosciences (NBIX) EV to EBITDA (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EV to EBITDA for 17 consecutive years, with 110.45 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA rose 40.24% year-over-year to 110.45; the trailing twelve-month figure through Jun 2026 stood at 21.05 (down 9.12% YoY), and the FY2025 full-year result was 20.54, down 6.19% from the prior year.
• EV to EBITDA rose to 110.45 in Q2 2026 per NBIX's latest filing, from 61.72 in the prior quarter.
• Across five years, EV to EBITDA topped out at 2673.62 in Q1 2022 and bottomed at 78.58 in Q1 2023.
• Historically, EV to EBITDA has averaged 243.01 across 5 years, with a median of 88.18 in 2024.
• The sharpest annual moves came in 2022 and 2023: EV to EBITDA surged 912.68% in 2022, then tumbled 102.94% in 2023.
• Over 5 years, EV to EBITDA stood at 101.83 in 2022, then slipped by 21.82% to 79.61 in 2023, then climbed by 10.51% to 87.97 in 2024, then tumbled by 31.46% to 60.3 in 2025, then soared by 83.18% to 110.45 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 110.45, 61.72, and 60.3 for Q2 2026, Q1 2026, and Q4 2025 respectively.